Engineering of bispecific affinity proteins with high affinity for ERBB2 and adaptable binding to albumin

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Nilvebrant, Johan ^a,b   Åstrand, Mikael ^a   Georgieva Kotseva, Maria ^a   Björnmalm, Mattias ^a,c   Löfblom, John ^a   Hober, Sophia ^a  

^a ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALBUMIN BINDING DOMAIN DERIVED AFFINITY PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; PEPTIDES AND PROTEINS; TRASTUZUMAB; UNCLASSIFIED DRUG; ALBUMINOID; BISPECIFIC ANTIBODY; MONOCLONAL ANTIBODY; PROTEIN BINDING;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DNA SEQUENCE; FLUORESCENCE ACTIVATED CELL SORTING; NONHUMAN; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN TARGETING; ANTIBODY AFFINITY; BINDING COMPETITION; CELL SURFACE DISPLAY; CHEMISTRY; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; TRANSITION TEMPERATURE; TUMOR CELL LINE;

ALBUMINS; AMINO ACID SEQUENCE; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY AFFINITY; BINDING, COMPETITIVE; CELL LINE, TUMOR; CELL SURFACE DISPLAY TECHNIQUES; FLOW CYTOMETRY; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN ENGINEERING; RECEPTOR, ERBB-2; TRANSITION TEMPERATURE;

EID: 84905457095     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103094     Document Type: Article

References (36)

1. Zahnd C, Pecorari F, Straumann N, Wyler E, Pluckthun A (2006) Selection and characterization of Her2 binding-designed ankyrin repeat proteins. J Biol Chem 281: 35167-35175. (Pubitemid 46036556)
2. Zahnd C, Wyler E, Schwenk JM, Steiner D, Lawrence MC, et al. (2007) A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J Mol Biol 369: 1015-1028. (Pubitemid 46754059)
3. Feldwisch J, Tolmachev V (2012) Engineering of affibody molecules for therapy and diagnostics. Methods Mol Biol 899: 103-126.
4. Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, et al. (2006) Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 66: 4339-4348.
5. Herschman HR (2003) Molecular imaging: looking at problems, seeing solutions. Science 302: 605-608.
6. Miao Z, Levi J, Cheng Z (2010) Protein scaffold-based molecular probes for cancer molecular imaging. Amino Acids 41: 1037-1047.
7. Schmidt MM, Wittrup KD (2009) A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 8: 2861-2871.
8. Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ (2012) Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol 503: 255-268.
9. Zahnd C, Kawe M, Stumpp MT, de Pasquale C, Tamaskovic R, et al. (2010) Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res 70: 1595-1605.
10. Kontermann RE (2011) Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 22: 868-876.
11. Frejd F (2012) Half-Life Extension by Binding to Albumin through an Albumin Binding Domain. In: Kontermann R, editor. Therapeutic Proteins: Strategies to Modulate Their Plasma Half- Lives. Weinheim: Wiley-VCH Verlag GmbH & Co.
12. Nygren P, Uhlén M, Flodby P, Andersson R, Wigzell H (1991) In vivo stabilization of a human recombinant CD4 derivative by fusion to a serum-albumin-binding receptor. Vaccines 91: 363-368.
13. Chaudhury C, Brooks CL, Carter DC, Robinson JM, Anderson CL (2006) Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Biochemistry 45: 4983-4990.
14. Nilsson FY, Tolmachev V (2007) Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Devel 10: 167-175. (Pubitemid 46438646)
15. Alm T, Yderland L, Nilvebrant J, Halldin A, Hober S (2010) A small bispecific protein selected for orthogonal affinity purification. Biotechnol J 5: 605-617.
16. Nilvebrant J, Alm T, Hober S, Lofblom J (2011) Engineering bispecificity into a single albumin-binding domain. PLoS One 6: e25791.
17. Nilvebrant J, Astrand M, Lofblom J, Hober S (2013) Development and characterization of small bispecific albumin-binding domains with high affinity for ErbB3. Cell Mol Life Sci 70: 3973-3985.
18. Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9: 463-475.
19. Nahta R (2012) New developments in the treatment of HER2-positive breast cancer. Breast Cancer: Targets and Therapy 4: 53-64.
20. Rosenstein R, Nerz C, Biswas L, Resch A, Raddatz G, et al. (2009) Genome analysis of the meat starter culture bacterium Staphylococcus carnosus TM300. Appl Environ Microbiol 75: 811-822.
21. Feldwisch J, Tolmachev V, Lendel C, Herne N, Sjoberg A, et al. (2010) Design of an optimized scaffold for affibody molecules. J Mol Biol 398: 232-247.
22. Gostring L, Malm M, Hoiden-Guthenberg I, Frejd FY, Stahl S, et al. (2012) Cellular effects of HER3-specific affibody molecules. PLoS One 7: e40023.
23. Gulich S, Linhult M, Nygren P, Uhlen M, Hober S (2000) Stability towards alkaline conditions can be engineered into a protein ligand. J Biotechnol 80: 169-178. (Pubitemid 30450150)
24. Kronqvist N, Lofblom J, Jonsson A, Wernerus H, Stahl S (2008) A novel affinity protein selection system based on staphylococcal cell surface display and flow cytometry. Protein Eng Des Sel 21: 247-255. (Pubitemid 351431053)
25. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, et al. (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756-760. (Pubitemid 36227628)
26. Eigenbrot C, Ultsch M, Dubnovitsky A, Abrahmsen L, Hard T (2010) Structural basis for high-affinity HER2 receptor binding by an engineered protein. Proc Natl Acad Sci U S A 107: 15039-15044.
27. Nilvebrant J, Hober S (2013) The albumin-binding domain as a scaffold for protein engineering. Comp Struct Biotech J 6.
28. He Y, Chen Y, Rozak DA, Bryan PN, Orban J (2007) An artificially evolved albumin binding module facilitates chemical shift epitope mapping of GA domain interactions with phylogenetically diverse albumins. Protein Sci 16: 1490-1494. (Pubitemid 46984883)
29. Lejon S, Frick IM, Bjorck L, Wikstrom M, Svensson S (2004) Crystal structure and biological implications of a bacterial albumin binding module in complex with human serum albumin. J Biol Chem 279: 42924-42928. (Pubitemid 39372183)
30. Kronqvist N, Malm M, Gostring L, Gunneriusson E, Nilsson M, et al. (2011) Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules. Protein Eng Des Sel 24: 385-396.
31. Jost C, Schilling J, Tamaskovic R, Schwill M, Honegger A, et al. (2013) Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2. Structure 21: 1979-1991.
32. Dennis MS, Jin H, Dugger D, Yang R, McFarland L, et al. (2007) Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res 67: 254-261. (Pubitemid 46142782)
33. Wozniak-Knopp G, Bartl S, Bauer A, Mostageer M, Woisetschlager M, et al. (2010) Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng Des Sel 23: 289-297.
34. Tolmachev V, Orlova A, Pehrson R, Galli J, Baastrup B, et al. (2007) Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res 67: 2773-2782. (Pubitemid 46548966)
35. Andersen JT, Pehrson R, Tolmachev V, Daba MB, Abrahmsen L, et al. (2011) Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J Biol Chem 286: 5234-5241.
36. Crooks GE, Hon G, Chandonia JM, Brenner SE (2004) WebLogo: a sequence logo generator. Genome Res 14: 1188-1190. (Pubitemid 38811555)